SEYSARA Drug Patent Profile

When do Seysara patents expire, and what generic alternatives are available?

Seysara is a drug marketed by Almirall and is included in one NDA. There are four patents protecting this drug.

This drug has seventy-three patent family members in twenty countries.

The generic ingredient in SEYSARA is sarecycline hydrochloride. One supplier is listed for this compound. Additional details are available on the sarecycline hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Seysara

Seysara was eligible for patent challenges on October 1, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 10, 2028. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for SEYSARA

International Patents:	73
US Patents:	4
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for SEYSARA

SEYSARA is protected by five US patents.

This potential generic entry date is based on patent 9,481,639.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Almirall	SEYSARA	sarecycline hydrochloride	TABLET;ORAL	209521-001	Oct 1, 2018		RX	Yes	No	8,513,223
Almirall	SEYSARA	sarecycline hydrochloride	TABLET;ORAL	209521-002	Oct 1, 2018		RX	Yes	No	9,481,639
Almirall	SEYSARA	sarecycline hydrochloride	TABLET;ORAL	209521-001	Oct 1, 2018		RX	Yes	No	8,318,706		Y	Y
Almirall	SEYSARA	sarecycline hydrochloride	TABLET;ORAL	209521-003	Oct 1, 2018		RX	Yes	Yes	8,318,706		Y	Y
Almirall	SEYSARA	sarecycline hydrochloride	TABLET;ORAL	209521-002	Oct 1, 2018		RX	Yes	No	8,513,223
Almirall	SEYSARA	sarecycline hydrochloride	TABLET;ORAL	209521-003	Oct 1, 2018		RX	Yes	Yes	8,513,223

International Patents for SEYSARA

When does loss-of-exclusivity occur for SEYSARA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

Cyprus

Denmark

European Patent Office

Lithuania

Poland

Portugal

Slovenia

Spain

Turkey

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SEYSARA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2007338747
Brazil	PI0720569
Canada	2673466
Canada	2925939
Canada	3051994
Denmark	2109602

Last updated: July 9, 2026

Seysara (sarecycline) investment scenario and patent fundamentals: exclusivity, Orange Book status, and generic risk

Seysara (sarecycline) is a next-generation tetracycline-class oral antibiotic for acne vulgaris that remains protected by a combination of compound and formulation IP and, in practice, Orange Book exclusivity buffers while FDA approvals cycle. The investment case hinges on (1) whether prescription share gains persist in branded acne therapy, (2) whether payer restrictions cap net price, and (3) how quickly ANDA challengers can align manufacturing and process constraints to launch at risk after patent or exclusivity windows.

---

What is Seysara (sarecycline) and how does it perform commercially vs. acne competitors?

Seysara is sarecycline, an oral tetracycline antibiotic approved for acne vulgaris. The investment lens for branded acne antibiotics is straightforward: durable dermatologist and primary-care adoption, rebate intensity/payer position, and formulary coverage dynamics against minocycline and doxycycline generics and branded comparators.

Key commercial drivers

• Formulary placement and reimbursement: branded antibiotics in acne are highly sensitive to payer step edits and prior authorization.
• Prescriber preference: uptake is driven by tolerability perceptions (GI effects) and prescribing workflows relative to older tetracyclines.
• Market structure: generics (doxycycline, minocycline, tetracycline classes) compress price ceilings; branded share depends on differentiation and payer acceptance.
• Safety and stewardship: antibiotic-resistance sentiment and stewardship policies affect institutional prescribing patterns.

Competitive set that shapes revenue exposure

• Generic oral tetracyclines: doxycycline, minocycline, tetracycline.
• Branded acne system therapies: depending on prescriber, combinations and retinoids/antimicrobials compete indirectly for adherence.
• Other oral anti-infectives in acne: market overlap exists with other antibiotics when patients fail first-line topical regimens.

---

What patents protect sarecycline (Seysara) in the US, and what is the estate strength?

A full US freedom-to-operate and IP strength assessment requires the complete US patent list and Orange Book entries for sarecycline and associated dosage forms. That record is the basis for estimating lifetimes, litigation posture, and generic launch pathways.

Patent estate fundamentals to underwrite

• Compound vs. formulation vs. method-of-use coverage: compound claims typically set the longest tail; formulation claims can block a workaround; method-of-use claims can block label-aligned ANDA designs.
• “Orange Book blocking” listings: the key dataset is whether patents are listed for the approved drug product and whether they cover the formulation, dosage, or use such that they are enforceable against ANDA products.
• Family depth: multiple continuation filings can extend protection by adding narrower claim sets, affecting litigation leverage even when broad claims face validity challenges.
• Expired or expiring first: the investment-risk trigger is the earliest date a challenger can launch safely if exclusivity/patent coverage falls away.

This response does not provide patent numbers, expiration dates, or listing-specific mapping because the required Orange Book and patent-bibliographic inputs for Seysara were not supplied in the prompt.

---

What is the Orange Book status of Seysara (sarecycline) and what exclusivities matter most?

For ANDA timing, the governing question is not only patent expiration but whether any 5-year or 3-year exclusivity is still running for the approved drug product or a supplemental approval, and which listed patents are enforceable for the specific NDA product.

Orange Book and exclusivity under a lender-style view

• Orange Book listing type: patents listed in connection with the NDA’s active ingredient and dosage form.
• Exclusivity stacking: patent term may outlast exclusivity, or exclusivity may outlast earlier patent filing gaps.
• Supplemental approvals: label changes supported by data can extend exclusivity even when some patents expire earlier.

This response does not enumerate the Seysara Orange Book listing set or exclusivity window because the underlying Orange Book data was not provided in the prompt.

---

When does Seysara lose exclusivity in the US, and when could generics launch?

Generic entry risk is timed to (1) the earliest enforceable patent expiration and (2) any applicable exclusivity that blocks ANDA marketing even if patents expire.

Launch scenarios used by investors

• No carve-out successful design: ANDA launch requires either no patent infringement or a successful Paragraph IV challenge leading to court decision or settlement-triggered dates.
• Design-around strategy: formulation or salt/process claims can force challengers into a different dosage form or manufacturing route, delaying commercialization even if some patents expire.
• Settlement and “authorized generic”: typical outcomes in branded antibiotic estates include settlement-triggered generic marketing dates and carve-outs.

This response does not provide specific dates for Seysara because the prompt does not include Seysara patent expiration and exclusivity data needed for accurate timing.

---

How many Paragraph IV ANDA challenges target sarecycline, and which companies are challenging?

For investment underwriting, the most decision-grade facts are:

• whether ANDA challengers have filed Paragraph IV certifications,
• which patents they target,
• whether litigation has progressed to claim construction or trial, and
• whether settlement has occurred.

This response does not provide a list of Paragraph IV filings, challengers, or litigation dates because the prompt lacks the necessary Seysara litigation and ANDA filing data.

---

What patent litigation affects Seysara (sarecycline) and what settlements changed generic entry risk?

Patent litigation changes the risk curve when:

• courts narrow claims,
• injunctions are threatened or stayed,
• settlements lock in a launch date, and
• authorized generics are licensed or permitted.

This response does not summarize Seysara-specific litigation or settlements because the prompt does not contain the required litigation docket details and settlement terms.

---

What formulations are protected by sarecycline patents (tablet composition, coating, polymorph, or process)?

For oral acne antibiotics, generic risk often turns on whether listed patents cover:

• tablet composition and excipient ranges,
• manufacturing process parameters that yield specific dissolution profiles,
• polymorph or solid-state form, if claimed,
• coating systems affecting release and bioavailability.

This response does not identify which Seysara dosage forms or formulations are protected because the prompt lacks the patent claims and Orange Book drug product mapping needed for that level of specificity.

---

How does sarecycline compare with doxycycline and minocycline generics in adoption and pricing power?

In branded acne antibiotics, differentiation tends to be payer-driven rather than mechanism-driven.

Practical comparison framework

• Clinical positioning: sarecycline’s value proposition in practice is tolerability and adherence support versus older tetracyclines.
• Net price sensitivity: branded antibiotics rely on rebate and contracting; payer shifts can compress net sales.
• Generic substitution pressure: any loosening of payer restrictions for generics pressures share.

This response does not include quantitative market share or net price figures because no commercial dataset was provided in the prompt.

---

Does sarecycline face biosimilar-like risks, and is it treated as biologics IP?

Seysara is a small-molecule oral antibiotic. It does not face biosimilar pathways.

Correct pathway mapping

• ANDA pathway governs generic small-molecule entry.
• No biosimilar IP construct applies; the biologics risk model is inapplicable.

---

What manufacturing and IP barriers can delay generic sarecycline beyond patent dates?

Even after patent or exclusivity windows, launch can be delayed by:

• stability and dissolution requirements,
• process validation complexity,
• quality system and bioequivalence study planning,
• regulatory inspection and CMC readiness timelines.

This response does not assess Seysara-specific manufacturing or CMC barriers because the prompt does not provide information on approved product manufacturing sites, CMC comparability disputes, or known ANDA technical findings.

---

Investment scenario: what must be true for upside vs. downside in Seysara?

Upside scenario (branded durability)

• Sustained dermatologist and primary-care prescribing with stable payer access.
• Continued clinical confidence versus generic substitution.
• No adverse regulatory signals affecting labeling scope or safety narrative.
• Patent estate and exclusivity prevent at-risk generic commercialization on an economically meaningful scale.

Downside scenario (share and price compression)

• Payer tightening shifts patients back to doxycycline/minocycline generics.
• A credible generic launch date becomes imminent through patent or settlement pathways.
• Label narrowing, stewardship policy constraints, or safety perceptions reduce persistence.

This response does not assign probability weights or quantify downside triggers because no patent-date dataset, NDA sales history, payer mix, or R&D pipeline context was provided in the prompt.

---

Key Takeaways

• Seysara’s investment risk is driven by US patent and Orange Book exclusivity mechanics, not by biosimilar-style pathways.
• Generic threat depends on how enforceable the listed patents are for the approved drug product and whether challengers can secure a court/settlement path.
• Near- to mid-term revenue durability depends on payer coverage and prescribing persistence against doxycycline and minocycline generics.

---

FAQs

1) What is the regulatory pathway for generic sarecycline (Seysara) in the US?
ANDA under the Hatch-Waxman framework for small-molecule drugs.

2) What evidence would typically support an at-risk ANDA launch for sarecycline?
A Paragraph IV certification paired with an ANDA-ready CMC package and bioequivalence plan aligned to the approved dosage form.

3) Do acne antibiotics like sarecycline face step edits or prior authorization trends?
They often do, based on payer policies that favor lower-cost tetracyclines when clinically interchangeable.

4) Are there formulation or solid-state factors that can block generic substitutes even after some patents expire?
Yes, when formulation or process claims are listed and enforceable for the approved dosage form.

5) What litigation milestones matter most for generic timing in acne antibiotic estates?
Claim construction outcomes, trial scheduling/decisions, and settlement-triggered dates.

---

References

No sources were provided in the prompt.